Glioma
|
0.700 |
Biomarker
|
disease |
BEFREE |
IDH2 mutations were associated with better outcomes compared with IDH wild-type gliomas (P < 0.05).
|
31833906 |
2019 |
Glioma
|
0.700 |
Biomarker
|
disease |
BEFREE |
Development and Validation of an IDH1-Associated Immune Prognostic Signature for Diffuse Lower-Grade Glioma.
|
31824866 |
2019 |
Glioma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
MATH values were increased in patients with glioma with the wild-type isocitrate dehydrogenase (NADP<sup>(+)</sup>) (IDH)1/2 (IDH-wt) gene (P=0.001) and glioblastoma (GBM; P=0.001).
|
31788085 |
2019 |
Glioma
|
0.700 |
Biomarker
|
disease |
BEFREE |
Novel IDH1-Targeted Glioma Therapies.
|
31768950 |
2019 |
Glioma
|
0.700 |
Biomarker
|
disease |
BEFREE |
Mutation of the isocitrate dehydrogenase (IDH) gene is regarded a novel indicator for the prognosis of patients with glioma.
|
31746408 |
2020 |
Glioma
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
In this study, we investigated the relationship between SWI features and glioma grades, and the expression of key molecular markers isocitrate dehydrogenase 1 (IDH1), O-6-methylguanine-DNA methyltransferase (MGMT), and 1p19q.
|
31745161 |
2019 |
Glioma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
In this study, using bioinformatics algorithms, we examined the chemical relationships between the amino acid sequences of the complementarity-determining region-3 (CDR3) represented by immune receptors associated with lower grade glioma and isocitrate dehydrogenase-1 (IDH1) mutants.
|
31740784 |
2020 |
Glioma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
For patients with IDH mutant 1p/19q codeleted LGG tumors, there is limited evidence to support the use of TMZ.
|
31701682 |
2020 |
Glioma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
IDH1/2 mutation status now represents the most important initial stratifier of diffuse gliomas in adults, although rarer subtypes within the IDH-wildtype category continue to be elucidated.
|
31678207 |
2020 |
Glioma
|
0.700 |
Biomarker
|
disease |
BEFREE |
A nomogram incorporating radiomics signature, IDH and age improved the performance of OS estimation, which might be a new complement to the treatment guidelines of glioma.
|
31606714 |
2019 |
Glioma
|
0.700 |
Biomarker
|
disease |
BEFREE |
An analysis of 2589 patient samples showed that CLEC5A expression is higher in (1) glioblastoma than in lower-grade glioma and nontumor tissue, (2) in the mesenchymal subtype than in other subtypes, and (3) in IDH1-wild type glioblastoma than in IDH1-mutated glioblastoma.
|
31591460 |
2019 |
Glioma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Blockade of glutathione metabolism in IDH1-mutated glioma.
|
31548295 |
2020 |
Glioma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
This theory also provides an explanation for some of the most perplexing observations, including the scarcity of proper model systems and the prevalence of IDH1 mutation in glioma.
|
31504231 |
2019 |
Glioma
|
0.700 |
Biomarker
|
disease |
BEFREE |
The review also focuses on the effect of 2-HG on glioma epigenetics, the cellular signaling involved in IDH1 mutant glioma cells and the therapeutic response seen in mutant IDH1(mIDH1) harboring glioma patients in comparison to the patients with wild-type IDH1.
|
31485826 |
2020 |
Glioma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Multivariate analysis incorporating tumor status based on the presence of <i>IDH</i> mutations, <i>TERT</i> promoter mutations, and 1p/19q codeletion showed that in lower-grade gliomas, high NLR predicted poorer survival for the triple-negative, IDH mutation only, TERT mutation only, and IDH and TERT mutation groups.
|
31444316 |
2019 |
Glioma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
PI3K/mTOR inhibition of IDH1 mutant glioma leads to reduced 2HG production that is associated with increased survival.
|
31324855 |
2019 |
Glioma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
IDH1/2 active site mutations confer a neomorphic enzyme activity producing the oncometabolite D-2-hydroxyglutarate (D-2HG), which generates the glioma CpG island methylation phenotype (G-CIMP).
|
31292202 |
2019 |
Glioma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
In clinical samples of gliomas with IDH1 mutation, levels of D-2-hydroxyglutarate (D-2HG) were increased significantly compared with gliomas without IDH mutation.
|
31278288 |
2019 |
Glioma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Mutations in the isocitrate dehydrogenase-1 gene (IDH1) occur at high frequency in grade II-III gliomas (LGGs).
|
31240524 |
2019 |
Glioma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Methylation and transcription patterns are distinct in IDH mutant gliomas compared to other IDH mutant cancers.
|
31222125 |
2019 |
Glioma
|
0.700 |
Biomarker
|
disease |
BEFREE |
IDH Inhibitors Target Common Glioma Mutation.
|
31217295 |
2019 |
Glioma
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
CD163 expression was up-regulated in IDH wild-type glioma and mesenchymal subtype.
|
31143523 |
2019 |
Glioma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
There is variability in survival within IDH mutant gliomas determined by chromosomal events.
|
31134296 |
2019 |
Glioma
|
0.700 |
Biomarker
|
disease |
BEFREE |
Therefore, MET uptake for glioma grading was more consistent for IDH1-wildtype tumours than for IDH1-mutant tumours.
|
31102001 |
2019 |
Glioma
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
Podoplanin Expression and IDH-Wildtype Status Predict Venous Thromboembolism in Patients with High-Grade Gliomas in the Early Postoperative Period.
|
31100523 |
2019 |